The Foundation welcomes the news that effective 1 October 2015, the PBS listing for Eylea® (aflibercept) has been expanded to include the treatment of people with macula edema from either diabetic retinopathy or central retinal vein occlusion.
Julie Heraghty, Chief Executive Officer, Macular Disease Foundation Australia said, "The Federal Government is to be congratulated for providing PBS reimbursement for a second anti-VEGF treatment for these important and potentially blinding diseases, giving patients access and affordability to highly effective therapies."
Diabetic eye disease is a common complication of diabetes and the leading cause of blindness among working age adults in Australia. Saving sight is essential to maintain quality of life and independence.
Central retinal vein occlusion is where one of the central veins in the retina becomes blocked, and can lead to a significant loss of vision and potentially blindness. It generally occurs in one eye only.
1 October 2015